Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 7/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1529787 | 1.00 | PTPN1 (0.55) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL27203728 | 0.92 | PTPN1 (0.52) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL27207214 | 0.92 | PTPN1 (0.52) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL23722980 | 0.86 | CTSS (0.60) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL270319 | 0.85 | CTSS (0.73) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL29907906 | 0.85 | CTSS (0.73) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL270318 | 0.85 | CTSS (0.73) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL1270141 | 0.85 | CTSS (0.73) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL29401585 | 0.85 | CTSS (0.73) | PTPN1ACECTSSCTSKPPARA | |
| SCHEMBL10477404 | 0.85 | ACE (0.56) | PTPN1ACECTSSCTSKPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-104781256-B | 3,4 pairs of substitution oxazolidinone derivatives and its purposes as the inhibitor of calcium-activated potassium channel | 霍夫曼-拉罗奇有限公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-104781256-A | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel | HOFFMANN LA ROCHE | 2015-07-15 | — | — | CN | disclosed |
| EP-1968568-A2 | INHIBITORS OF Akt ACTIVITY | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| EP-0720601-B1 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2000-10-25 | — | — | EP | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | PTPN1 201/4885ACE 831/4885CTSS 2182/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | PTPN1 201/4885ACE 831/4885CTSS 2182/4885 |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | PTPN1 2971/4885ACE 74/4885CTSS 4/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | PTPN1 201/4885ACE 831/4885CTSS 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.